SCI时时刷

search
+
rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors
IntroductionGenetically engineered T cells expressing a chimeric antigen receptor (CAR) are an emerging immunotherapy for ...
Peptide-based PET tracer targeting LAG-3 for evaluating the efficacy of immunotherapy in melanoma
WHAT IS ALREADY KNOWN ON THIS TOPICLymphocyte activation gene 3 (LAG-3) is a novel target for immune checkpoint blocking. ...
Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma
WHAT IS ALREADY KNOWN ON THIS TOPICDirecting chimeric antigen receptor (CAR) T cells against solid tumors has been largely...
Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma
BackgroundMetastatic/unresectable urothelial carcinoma (mUC) is detected in approximately 20% of cases of invasive UC.1 Co...
Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy
Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine cancer increasing in incidence to about 3,000 cases ...
Immune cell topography of head and neck cancer
BackgroundHead and neck squamous cell carcinoma (HNSCC) has a poor prognosis with a recurrence rate of approximately 50% a...
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells
BackgroundNatural killer (NK) cells are innate lymphocytes that use germline-encoded receptors to interrogate cells of the...
Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers
WHAT IS ALREADY KNOWN ON THIS TOPICImmunosuppressive conditions within the tumor microenvironment hamper the effectiveness...
Acknowledging and addressing real-world challenges to treating immune-related adverse events
More than a decade into the remarkable era of cancer immunotherapy, we are facing major challenges with the toxicities of ...
Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer
IntroductionOral squamous cell carcinoma (OSCC) originates in the mucosal lining of the mouth and affects more than 370,00...
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors
IntroductionImmunotherapies have revolutionized the field of oncology1 with immune checkpoint inhibitors being approved fo...
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases
WHAT IS ALREADY KNOWN ON THIS TOPICToll-like receptor 9 class C (TLR9C) agonists delivered regionally using an intravascul...
Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors
IntroductionImmune checkpoint inhibitors (ICIs) targeting key checkpoint receptors responsible for immune system downregul...
Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapy
IntroductionNatural killer (NK) cells mediate defenses against pathogens and cancer cells.1 During the past two decades, w...
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
Defining PD-(L)1 inhibitor resistanceWhile many patients treated with programmed death-ligand 1 (PD-(L)1) inhibitors achie...
Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors?
The development of immunotherapy caused a paradigm shift in treating different types of metastatic cancers. Immune checkpo...
Cantharidin overcomes IL-2R{alpha} signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species
IntroductionCutaneous T-cell lymphoma (CTCL), a rare non-Hodgkin’s lymphoma derived from T cell, can be divided into the m...
Novel insights into paclitaxels role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment
BackgroundTriple-negative breast cancer (TNBC) is identified by the lack of estrogen, progesterone, and HER2 receptors, ma...
Assessing the implications of sentinel lymph node removal in cervical cancer: an immunogenetic perspective - a SENTICOL ancillary study
WHAT IS ALREADY KNOWN ON THIS TOPICWHAT THIS STUDY ADDSWe applied the nCounter PanCancer Immune Profiling panel on 36 SLN ...
Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy
IntroductionHepatocellular carcinoma (HCC) as the primary form of liver cancer, accounting for 75%–85%, represents the six...
Generation of non-genetically modified, CAR-like, NK cells
IntroductionNatural killer (NK) cell therapy using ex vivo expanded allogeneic NK cells is an established anticancer strat...
A crisis in clinical research
IntroductionA patient with cancer in their 70s was diagnosed with chemotherapy and immune checkpoint inhibitor (ICI)-refra...
Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors
IntroductionLung cancer remains to have the highest incidence among cancers in men and leading cause of cancer-related dea...
Correction: ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3
Ao Y, Gao J, Jin C, et al. ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing...
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines
The development of vaccines directed against neoepitopes of solid tumors has recently been and continues to be an active a...
Harnessing lipid metabolism modulation for improved immunotherapy outcomes in lung adenocarcinoma
BackgroundDespite significant advancements in treatment, lung cancer continues to be the leading cause of cancer-related d...
Genetically engineering glycolysis in T cells increases their antitumor function
BackgroundA large body of studies in humans and mice has established that CD8+ T cells can control tumor progression.1 Dif...
Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update
IntroductionImmune checkpoint inhibitors (ICIs) are now approved for at least 17 different cancer types, and have resulted...
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations
IntroductionAntibody immunotherapy now benefits a proportion of patients with cancer, most notably after checkpoint blocka...
Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin
IntroductionImmunotherapy strategies such as immune checkpoint blockades and adoptive immune cell transfer (ACT) that aim ...
阅读更多
format_indent_increase